

## **Pediatric CIRB Meeting Agenda**

**April 8, 2021**

---

---

### **I. Continuing Review**

**AGCT1531**, A Phase 3 Study of Active Surveillance for Low risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors (Protocol Version Date 10/26/20)

---

---

### **II. Continuing Review**

**ANBL19P1**, A Pilot Study of Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination with Irinotecan and Temozolomide in the Post-Consolidation Setting for High-Risk Neuroblastoma (Protocol Version Date 07/15/20)

---

---

### **III. Continuing Review**

**APEC1621A**, NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-101 (Larotrectinib) in Patients with Tumors Harboring Actionable NTRK Fusions (Protocol Version Date 10/07/19)

---

---

### **IV. Continuing Review**

**APEC1621B**, NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 subprotocol of JNJ-42756493 (Erdafitinib) in patients with tumors harboring FGFR1/2/3/4 alterations (Protocol Version Date 03/08/19)

---

---

### **V. Continuing Review**

**APEC1621C**, NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 subprotocol of tazemetostat for patients with tumors harboring alterations in EZH2 or members of the SWI/SNF complex (Protocol Version Date 07/20/20)

---

---

---

---

**VI. Continuing Review**

**APEC1621D**, NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 subprotocol of LY3023414 in Patient with Solid Tumors (Protocol Version Date 03/12/21)

---

---

**VII. Continuing Review**

**APEC1621E**, NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 subprotocol of Selumetinib (AZD6244 Hydrogen Sulfate) in patients with Tumors harboring activating MAPK pathway mutations (Protocol Version Date 08/19/19)

---

---

**VIII. Continuing Review**

**APEC1621F**, NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Ensartinib in Patients with Tumors harboring ALK or ROS1 Genomic Alterations (Protocol Version Date 08/12/20)

---

---

**IX. Continuing Review**

**APEC1621G**, NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 subprotocol of Vemurafenib in patients with tumors harboring BRAF V600 mutations (Protocol Version Date 11/10/20)

---

---

**X. Continuing Review**

**APEC1621H**, NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Olaparib in Patients with Tumors Harboring Defects in DNA Damage Repair Genes (Protocol Version Date 05/23/19)

---

---

**XI. Continuing Review**

**APEC1621I**, NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 subprotocol of Palbociclib in Patients with Tumors Harboring Activating Alterations in Cell Cycle Genes (Protocol Version Date 11/26/19)

---

---

---

---

**XII. Continuing Review**

**APEC1621J**, NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of BVD-523FB (ulixertinib) in Patients with Tumors Harboring Activating MAPK Pathway Mutations (Protocol Version Date 12/9/20)

---

---

**XIII. Continuing Review**

**APEC1621K**, NCI-COG Pediatric Molecular Analysis for Therapy Choice MATCH - Phase 2 subprotocol of AG-120 (ivosidenib) in Patients with Tumors harboring IDH1 mutations (Protocol Version Date 09/28/20)

---

---

**XIV. Continuing Review**

**APEC1621M**, NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 subprotocol of Tipifarnib in Patients with Tumors Harboring HRAS Genomic Alterations (Protocol Version Date 12/11/20)

---

---

**XV. Continuing Review**

**APEC1621N**, NCI-COG Pediatric Molecular Analysis for Therapy Choice (MATCH) – Phase 2 Subprotocol of LOXO-292 in Patients Harboring RET Gene Alterations (Protocol Version Date 10/23/20)

---

---

**XVI. Continuing Review**

**APEC1621SC**, NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol (Protocol Version Date 03/11/20)

---

---

**XVII. New Study ReReview**

**ACNS2021**, A Phase 2 Trial of Chemotherapy followed by Response-Based Whole Ventricular & Spinal Canal Irradiation (WVSCI) for Patients with Localized Non-Germinomatous Central Nervous System Germ Cell Tumor (Protocol Version Date 03/10/21)

---

---